Skip to main content

Table 1 Sociodemographic and clinical characteristics of 251 women included, according to menopausal status

From: How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

   Menopausal status  
All women Pre-menopausal Peri-menopasual Post-menopausal p
251 (100%) 44 (17.5%) 70 (27.9%) 137 (54.6%)  
Sociodemographic variables      
Age (years; median –[IQR]) 52 (48–55) 46 (45–48) 49 (47–52) 55 (52–57) < 0.001
Country of origin      
 Spain 187 (74.5%) 26 (59.1%) 53 (75.7%) 108 (78.8%) 0.032
 Others 64 (25.5%) 18 (40.9%) 17 (24.3%) 29 (21.2%)  
Educational level      
 None or primary 21 (8.4%) 2 (4.5%) 7 (10.0%) 12 (8.8%) 0.574
 Secondary or university 230 (91.6%) 42 (95.5%) 63 (90.0%) 125 (91.2%)  
Current occupational status      
 Employed 137 (54.6%) 24 (54.5%) 41 (58.6%) 72 (52.6%) 0.525
 Unemployed 45 (17.9%) 11 (25.0%) 11 (15.7%) 23 (16.8%)  
 Other* 69 (27.5%) 9 (20.5%) 18 (25.7%) 42 (30.7%)  
Current partner and cohabitation status      
 Without partner 106 (42.2%) 16 (36.4%) 19 (27.1%) 71 (51.8%) 0.004
 With partner and living together 108 (43.0%) 24 (54.5%) 35 (50.0%) 49 (35.8%)  
 With partner and not living together 37 (14.7%) 4 (9.1%) 16 (22.9%) 17 (12.4%)  
Clinical variables      
Body mass index (kg/m2)      
 < 18.5 15 (6.0%) 3 (6.8%) 2 (2.9%) 10 (7.3%) 0.482
 18.5–24.9 136 (54.2%) 23 (52.3%) 39 (55.7%) 74 (54.0%)  
 25–30 54 (21.5%) 10 (22.7%) 20 (28.6%) 24 (17.5%)  
 > 30 39 (15.5%) 6 (13.6%) 7 (10.0%) 26 (19.0%)  
 Unknown 7 (2.8%) 2 (4.5%) 2 (2.9%) 3 (2.2%)  
Body mass index (kg/m2) 23.7 (21.2–28.0) 24.0 (22.0–26.7) 23.8 (21.2–27.7) 23.6 (21.0–28.7) 0.982
Hepatitis B      
 Yes 60 (23.9%) 6 (13.6%) 18 (25.7%) 36 (26.3%) 0.335
 No 174 (69.3%) 33 (75.0%) 47 (67.1%) 94 (68.6%)  
 Unknown 17 (6.8%) 5 (11.4%) 5 (7.1%) 7 (5.1%)  
Hepatitis C      
 Yes 60 (23.9%) 6 (13.6%) 16 (22.9%) 38 (27.7%) 0.204
 No 179 (71.3%) 34 (77.3%) 50 (71.4%) 95 (69.3%)  
 Unknown 12 (4.8%) 4 (9.1%) 4 (5.7%) 4 (2.9%)  
Diabetes mellitus      
 Yes 18 (7.2%) 2 (4.5%) 4 (5.7%) 12 (8.8%) 0.549
 No 233 (92.8%) 42 (95.5%) 66 (94.3%) 125 (91.2%)  
Osteoporosis      
 Yes 37 (14.7%) 0 (0.0%) 7 (10.0%) 30 (21.9%) < 0.001
 No 214 (85.3%) 44 (100.0%) 63 (90.0%) 107 (78.1%)  
Smoking      
 Current 115 (45.8%) 15 (34.1%) 35 (50.0%) 65 (47.4%) 0.215
 Never/past 136 (54.2%) 29 (65.9%) 35 (50.0%) 72 (52.6%)  
Alcohol consumption      
 Never/occasional (< 2 times/week) 202 (80.5%) 36 (81.8%) 56 (80.0%) 110 (80.3%) 0.969
 Frequent (≥ 2 times/week) 49 (19.5%) 8 (18.2%) 14 (20.0%) 27 (19.7%)  
Drug use      
 Never 154 (61.4%) 27 (61.4%) 43 (61.4%) 84 (61.3%) 0.522
 Sporadic use 8 (3.2%) 3 (6.8%) 3 (4.3%) 2 (1.5%)  
 Regular past use 75 (29.9%) 13 (29.5%) 21 (30.0%) 41 (29.9%)  
 Regular current use 14 (5.6%) 1 (2.3%) 3 (4.3%) 10 (7.3%)  
Trouble failing asleep the last two weeks      
 Never 137 (54.6%) 28 (63.6%) 44 (62.9%) 65 (47.4%) 0.165
 Less than twice a week 29 (11.6%) 5 (11.4%) 6 (8.6%) 18 (13.1%)  
 More than 3 times a week 85 (33.9%) 11 (25.0%) 20 (28.6%) 54 (39.4%)  
Social support (MOS-SSS-4item)      
 Poor(score < 12) 43 (17.1%) 8 (18.2%) 4 (5.7%) 31 (22.6%) 0.009
 Normal(score ≥ 12) 208 (82.9%) 36 (81.8%) 66 (94.3%) 106 (77.4%)  
Sexual intercourse during last year      
 Yes 159 (63.3%) 33 (75.0%) 56 (80.0%) 70 (51.1%) < 0.001
 No 92 (36.7%) 11 (25.0%) 14 (20.0%) 67 (48.9%)  
Age at diagnosis (years; median[IQR]) 42 (38–46) 39 (36.5–42) 40 (36–44) 45 (39–49) < 0.001
HIV transmission mode      
 Injecting drug user 30 (12.0%) 3 (6.8%) 10 (14.3%) 17 (12.4%) 0.293
 Heterosexual 210 (83.7%) 37 (84.1%) 59 (84.3%) 114 (83.2%)  
 Others/Unknown 11 (4.4%) 4 (9.1%) 1 (1.4%) 6 (4.4%)  
Time since HIV diagnoses (years)      
 < 5 44 (18%) 10 (22.7%) 11 (15.7%) 23 (16.8%) 0.667
 5–10 85 (34%) 17 (38.6%) 24 (34.3%) 44 (32.1%)  
 > 10 122 (49%) 17 (38.6%) 35 (50.0%) 70 (51.1%)  
Antiretroviral treatment      
 Yes 236 (94%) 42 (95.5%) 66 (94.3%) 128 (93.4%) 0.88
 No 15 (6%) 2 (4.5%) 4 (5.7%) 9 (6.6%)  
Time with ART (years)      
 Median (IQR) 7.5 (4.8–10.5) 6.8 (4.2–10.1) 7.8 (5.2–10.3) 7.5 (4.6–10.6) 0.471
ART adherence      
 All pills 222 (94.1%) 39 (92.9%) 60 (90.9%) 123 (96.1%) 0.407
 Most of them 11 (4.7%) 3 (7.1%) 4 (6.1%) 4 (3.1%)  
 Half of them or less 3 (1.3%) 0 (0.0%) 2 (3.0%) 1 (0.8%)  
AIDS diagnosis      
 Yes 52 (20.7%) 7 (15.9%) 14 (20.0%) 31 (22.6%) 0.623
 No 199 (79.3%) 37 (84.1%) 59 (84.3%) 106 (77.4%)  
CD4 count at last visit (cells/µl)      
 < 200 7 (2.8%) 0 (0.0%) 1 (1.4%) 6 (4.4%) 0.484
 200–500 60 (23.9%) 11 (25.0%) 15 (21.4%) 34 (24.8%)  
 > 500 184 (73.3%) 33 (75.0%) 54 (77.1%) 97 (70.8%)  
Median (IQR) 720 (491–960) 663 (500–925.5) 719.5 (527–959) 731 (476–1016) 0.929
Viral load at last visit      
 Undetectable(≤ 200 copies/µl) 234 (93.2%) 41 (93.2%) 68 (97.1%) 125 (91.2%) 0.279
 Detectable(> 200 copies/µl) 17 (6.8%) 3 (6.8%) 2 (2.9%) 12 (8.8%)  
Womens health variables      
Age at menarche (years)      
 < 13 98 (39%) 16 (36.4%) 28 (40.0%) 54 (39.4%) 0.990
 ≥ 13 149 (59%) 27 (61.4%) 41 (58.6%) 81 (59.1%)  
 Unknown 4 (02%) 1 (2.3%) 1 (1.4%) 2 (1.5%)  
Number of pregnancies      
 None 36 (14.3%) 7 (15.9%) 13 (18.6%) 16 (11.7%) 0.344
 1 or 2 114 (45.4%) 17 (38.6%) 27 (38.6%) 70 (51.1%)  
 ≥ 3 101 (40.2%) 20 (45.5%) 30 (42.9%) 51 (37.2%)  
  1. Bold values are statistically significant
  2. IQR interquartile range, ART antiretroviral therapy, AIDS acquired immunodeficiency syndrome
  3. *Other: retired, housewife, students